Can the CSL share price crack a new, all-time high in 2023?

Two ASX brokers rate CSL shares as a buy today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The CSL share price last hit an all-time high way back in pre-COVID 2020
  • But the ASX 200 healthcare giant has failed to even come close to $342.75 a share in the three-and-a-half years since
  • ASX brokers are generally positive on CSL shares today, but opinions are divided on whether the company can crack another record high in 2023

It's starting to seem like a long time since the CSL Ltd (ASX: CSL) share price cracked a new, all-time record high. Today, this ASX 200 healthcare share is trading at $304.17 (at the time of writing). That is a share price CSL first hit way back in January 2020.

At the time, CSL hitting $300 was big news But it has crossed this proverbial Rubicon so many times since that it is now a non-event. In fact, CSL's last all-time high came in early 2020 as well. On 20 February, the healthcare giant hit an intra-day high of $342.75 a share – what seemed like the latest in a long string of new record highs for the company.

But when it comes to that high watermark, CSL has barely come close in the three-and-a-bit years since:

So is it possible for CSL to regain its former mojo and exceed $342.75 per share in 2023 to a new all-time high?

a climber scales a sheer rock cliff face reaching out for a handhold with foreboding grey clouds gathering in the sky above him.

Image source: Getty Images

Is a new all-time high coming for this ASX 200 healthcare share?

Well, at least one ASX broker certainly thinks so. As my Fool colleague James covered late last month, broker Morgans currently has an add rating on the CSL share price. Although acknowledging CSL had some significant issues during the worst throes of the COVID pandemic, Morgans now anticipates these difficulties are behind the company.

The broker points to increased plasma collections, higher interest in influenza vaccines, and new product development as factors that it sees leading to "double-digit recovery in earnings growth".

Share price wise, Morgans points to CSL's valuation, stating that the "shares [are] offering good value trading around its long-term forward multiple of ~30x".

But Morgans has a 12-month share price target of $337.92 for CSL right now. Although that would represent a pleasing bounce from the current share price, it still falls short of CSL's reining record high.

As such, perhaps investors might be more inclined to follow the projections of another ASX broker in Citi. Citi also rates CSL shares as a buy today. But this broker has an improved share price target of $350 a share. That would of course be a new all-time high for the ASX 200 healthcare veteran.

If we accept these brokers' views, it does seem possible that CSL will close out 2023 with a new record share price under its belt (or at least close to it). But we'll just have to wait and see if Morgans and Citi are on the money, or if CSL spends another year meandering around the $300 a share mark.

CSL share price snapshot

The CSL share price has been a solid performer in 2023 so far, gaining more than 7.8% since the start of the year. The company is also up around 12.4% over both the past 12 and 24 months.

At the current CSL share price, this ASX 200 healthcare giant has a market capitalisation of $145.88 billion, with a dividend yield of 0.95%.

 

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

Down 43% this week, are Cochlear shares now the best bargain buy of the year?

A leading analyst believes the historic selloff in Cochlear shares could present a unique buying opportunity.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Down 50%, why I'd invest $20,000 into CSL shares

A 50% decline in a blue-chip share can signal trouble, but not always a broken story.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech stock could deliver 40%-plus returns Morgans says

This small company continues to kick goals.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Healthcare Shares

How high could Cochlear shares bounce back? Brokers disagree

Despite bad news on the earnings front this week, Cochlear shares could still deliver upside.

Read more »

Retired couple hugging and laughing.
Healthcare Shares

A Budget announcement has put a rocket under this ASX aged care provider's shares

A shake up in the funding model will be a boost for this company.

Read more »

An arrow crashes through the ground as a businessman watches on.
Healthcare Shares

Cochlear stock down 40%: How much has this cost ASX investors?

One day can ruin years of success...

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

What on earth's going on with Pro Medicus shares?

The quality stock is now driven heavily by expectations.

Read more »

A stressed businessman sits next to his briefcase with his head in his hands, while the ASX boards behind him show shares crashing.
52-Week Lows

CSL's collapse deepens. Why this ASX giant can't find a floor

CSL shares hit a 9-year low as new demand concerns emerge.

Read more »